[{"orgOrder":0,"company":"Myung In Pharm","sponsor":"Pharma Two B","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Pramipexole Dihydrochloride","moa":"||D2-like dopamine receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Myung In Pharm","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Oral Capsule","sponsorNew":"Myung In Pharm \/ Myung In Pharm","highestDevelopmentStatusID":"10","companyTruncated":"Myung In Pharm \/ Myung In Pharm"},{"orgOrder":0,"company":"Myung In Pharm","sponsor":"Newron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Licensing Agreement","leadProduct":"Evenamide","moa":"Sodium channel alpha subunit","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Myung In Pharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Myung In Pharm \/ Myung In Pharm","highestDevelopmentStatusID":"8","companyTruncated":"Myung In Pharm \/ Myung In Pharm"},{"orgOrder":0,"company":"Myung In Pharm","sponsor":"Luye Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Partnership","leadProduct":"Rivastigmine","moa":"Cholinesterases; ACHE & BCHE","graph1":"Neurology","graph2":"Approved FDF","graph3":"Myung In Pharm","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Myung In Pharm \/ Myung In Pharm","highestDevelopmentStatusID":"15","companyTruncated":"Myung In Pharm \/ Myung In Pharm"}]

Find Clinical Drug Pipeline Developments & Deals by Myung In Pharm

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          CPHI Shenzhen
                          Not Confirmed
                          CPHI Shenzhen
                          Not Confirmed

                          Details : Under the licensing agreement, Myung will develop, manufacture, and commercialize Newron’s NW-3509 (evenamide) for patients with schizophrenia in South Korea.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          January 09, 2025

                          Lead Product(s) : Evenamide

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase II

                          Recipient : Newron Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          02

                          CPHI Shenzhen
                          Not Confirmed
                          CPHI Shenzhen
                          Not Confirmed

                          Details : The partnership aims to develop and commercialise of Rivalif (rivastigmine) twice weekly transdermal patch in South Korea for mild to moderate dementia associated with Alzheimer's disease.

                          Product Name : Rivalif

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          May 02, 2024

                          Lead Product(s) : Rivastigmine

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved FDF

                          Recipient : Luye Pharma

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          03

                          CPHI Shenzhen
                          Not Confirmed
                          CPHI Shenzhen
                          Not Confirmed

                          Details : Under the terms of the agreement, Myung In Pharm will seek regulatory approval for P2B001 in South Korea and will manufacture, commercialize and distribute P2B001 in the region.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          November 18, 2021

                          Lead Product(s) : Pramipexole Dihydrochloride,Rasagiline Mesylate

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase III

                          Recipient : Pharma Two B

                          Deal Size : $5.0 million

                          Deal Type : Licensing Agreement

                          blank